ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
Dow Jones
38.686,32
1,51%
Euro vs US Dollar
1,08565
0,00%
Bitcoin
67.741,62
0,02%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Vallon Pharmaceuticals Inc (VLON)

  7. Vallon Pharmaceuticals Inc (VLON) News

VLON

Vallon Pharmaceuticals (VLON)

Vallon Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:VLON
DatumZeitQuelleÜberschriftSymbolFirma
31/05/202421h34Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:VLONVallon Pharmaceuticals Inc
31/05/202421h32Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:VLONVallon Pharmaceuticals Inc
22/05/202422h45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VLONVallon Pharmaceuticals Inc
20/05/202422h13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VLONVallon Pharmaceuticals Inc
20/05/202422h11Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VLONVallon Pharmaceuticals Inc
17/05/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:VLONVallon Pharmaceuticals Inc
17/05/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:VLONVallon Pharmaceuticals Inc
14/05/202422h46Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:VLONVallon Pharmaceuticals Inc
14/05/202422h44Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:VLONVallon Pharmaceuticals Inc
13/05/202414h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VLONVallon Pharmaceuticals Inc
10/05/202423h24Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:VLONVallon Pharmaceuticals Inc
10/05/202422h53Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VLONVallon Pharmaceuticals Inc
09/05/202422h31Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:VLONVallon Pharmaceuticals Inc
01/04/202415h13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VLONVallon Pharmaceuticals Inc
28/03/202421h45Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:VLONVallon Pharmaceuticals Inc
28/03/202421h42Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:VLONVallon Pharmaceuticals Inc
02/02/202422h25Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:VLONVallon Pharmaceuticals Inc
02/02/202422h23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VLONVallon Pharmaceuticals Inc
02/02/202422h21Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:VLONVallon Pharmaceuticals Inc
02/02/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:VLONVallon Pharmaceuticals Inc
30/01/202414h13Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:VLONVallon Pharmaceuticals Inc
30/01/202414h12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VLONVallon Pharmaceuticals Inc
19/01/202422h16Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:VLONVallon Pharmaceuticals Inc
19/01/202422h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VLONVallon Pharmaceuticals Inc
16/01/202414h45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VLONVallon Pharmaceuticals Inc
20/12/202323h12Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:VLONVallon Pharmaceuticals Inc
18/12/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:VLONVallon Pharmaceuticals Inc
15/12/202323h02Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:VLONVallon Pharmaceuticals Inc
05/12/202315h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VLONVallon Pharmaceuticals Inc
27/11/202314h38Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VLONVallon Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:VLON

Kürzlich von Ihnen besucht

CCOM
US100
US Tech 100
TG
TUI1
Tui
NASDAQ
AMZN
Amazon.com
NYSE
XOM
Exxon Mobil
NYSE
NKE
Nike
TG
MBG
MercedesBenz
NASDAQ
NVDA
NVIDIA
USOTC
RHHBY
Roche (QX)
TG
D7G
Nel ASA
DBI
SDXP
SDAX
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NASDAQ
MSFT
Microsoft
TG
ALV
Allianz
USOTC
BASFY
BASF (QX)
NYSE
KO
Coca Cola
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten